Acadia Pharmaceuticals Inc., originally incorporated in Vermont in 1993, was re-incorporated in Delaware in 1997. Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative micromolecular drugs to address unmet medical needs in neurological and central nervous system diseases. The company has two core businesses in neurological diseases and rare diseases. The core product of its neurological disease business is the marketed NUPLAZID (Pimo Panserin), which is the first and currently the only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions related to Parkinson's disease psychosis (PDP). The core product of its rare disease business is the marketed DAYBUE, which is the first and currently the only drug approved for the treatment of Rett syndrome. In addition to these marketed products, the company has a portfolio of product candidates and research programs designed to address significant unmet medical needs in the field of neurological diseases and rare diseases.